Investor Overview

PTI (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$14.77
Change (%)0.00 (0.00%)
Volume0
Data as of 08/25/16 4:00 p.m. ET
Corporate Profile

Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Our initial therapeutic focus is on cystic fibrosis, or CF, which is caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. ... More >>

Recent NewsMore >>
Proteostasis Therapeutics Issues Mid-Year Corporate Update on Cystic Fibrosis Pipeline Programs
August 11, 2016
Read More


Proteostasis Therapeutics Achieves Preclinical Milestone in Astellas Pharma Collaboration
August 08, 2016
Read More


Proteostasis Therapeutics Announces Key Leadership Appointments
August 08, 2016
Read More


Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
INVESTORS & MEDIA